An observational study in Advanced or Metastatic Renal Cell Carcinoma, sponsored by Ipsen. Active, not recruiting at 20 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Ipsen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Carcinoma, Renal Cell by Ipsen — none open to participants now, 2 under way, none of them phase 3. Carcinoma, Renal Cell · Ipsen.
Among the 16 studies in Carcinoma, Renal Cell by Ipsen, this one is the 10th largest by planned enrollment of the 13 observational ones that give a count, is one of 5 that started in 2020, is one of 13 observational ones, and was the 10th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.
Browse Carcinoma, Renal Cell studies →None of the 16 studies in Carcinoma, Renal Cell by Ipsen is open now. The open studies under Carcinoma, Renal Cell, anywhere →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.
Median enrollment 164 across the 2 interventional studies, 252 across the 13 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ipsen is the lead sponsor of 290 studies on the registry; 18 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
2 of the studies in Carcinoma, Renal Cell by Ipsen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04106349IpsenObservational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC) | 2027-03-31 |
| NCT03647878IpsenStudy of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Carcinoma, Renal Cell by Ipsen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)
advanced or metastatic renal cell carcinoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study also gives Nivolumab, Cabozantinib. No intervention listed here names it: that was found by reading the record.
Treatment line
Treatment line will be assessed at baseline. It is a percentage of patients receiving cabozantinib as 1st, 2nd or later lines of treatment or cabozantinib in monotherapy or in combination with nivolumab as 1st line of treatment.
Time frame: Baseline
Dose reductions and reasons
Number of dose reductions and reason
Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Treatment interruptions and reason
Number of treatment interruptions and reason
Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Treatment discontinuations and reason
Number of patients with permanent discontinuation and reason
Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Alternative dose schedule
Number of patients with schedules other than 1 pill at fixed dose/day for the total treatment period
Time frame: From baseline until the end of study up to 9 months
Mean number of any dose modification
Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median number of any dose modification
Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median time to any first dose modification
Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median time to end of treatment
Time frame: From baseline until the end of study up to 9 months
Duration of treatment exposure
Time frame: From baseline until the end of study up to 9 months
Dose prescribed at initiation
Number of patients with dose of 60 mg/day, 40 mg/day or 20 mg/day at baseline
Time frame: Baseline
Average daily dose
Estimation of average daily dose received by subject during the treatment exposure
Time frame: From baseline until the end of study up to 9 months
Change in Quality of Life score
Changes in quality of life data by comparing changes in scores on Using the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (NFKSI-19). It describes the severity, interference, and frequency rates.
Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Progression Free Survival (PFS)
Radiological progression using RECIST 1.1 or investigator assessed or according to local standard of care or death; PFS evaluated at least every 12 weeks under treatment with cabozantinib
Time frame: From baseline until the end of study up to 9 months
Objective Response Rate
Percent of patients with partial and complete response during the treatment with cabozantinib
Time frame: From baseline until the end of study up to 9 months
Disease Control Rate
Percent of patients with stable disease, partial and complete response during the treatment with cabozantinib
Time frame: From baseline until the end of study up to 9 months
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Started Mar 2020 (actual). Primary completion is estimated for Mar 2027, 84 months after the start.
Of 42 industry-sponsored observational studies under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 91. This study's planned 84 months is above that.
Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.